Member Info for Balanced66

A4UK

Yes that's possible they may be modifying it for the Q16 and 32 - the RNS suggests it's something they are still developing as it says the "objective" is to and it "plans" to.

RNS also says: "As a result, the laboratory products will be "ready-to-use".

So one step and more than one new product?

Back to bed now for me!

This is from the 2000 patient trial RNS. Apologies if it's already been discussed. But it looks like the company is developing pre-prepared tests that don't require any mixing to extract RNS etc as reaction tubes etc will come "coated". Sounds really good to me and another evolution of the covid test? Need someone with a scientific background to comment on it if it has not already been discussed - it probably has already and I've missed it I reckon?
"Novacyt's objective is therefore to develop a system with a reduced number of workflow steps for NPT. The Company plans to use its expertise in PCR testing to coat and stabilise the essential biological components required for its COVID-19 test onto laboratory products, such as reaction tubes. As a result, the laboratory products will be "ready-to-use" on Novacyt's q16 and q32 portable instruments and will only require the addition of a small amount of patient sample to initiate the COVID-19 test."

With the care home "trial" it may also be a way for the government\Doctors to say to care homes this trial has shown the benefits of portable testing over the 48 hours method and therefore provide a basis for a national roll-out? The government has received a lot of flack over the care homes testing and this provides a way out. Just some random thoughts really.

The Q16 and Q32 machines have already been in use for a number of years (link below mentions 2015) and have had strong sales in the past - this was before covid, sales could now really take off! If the technology works and there have been no concerns raised by the company to date since the previous launches of the product; if it didn't work then we would have heard about it by now.

The care home trial is to see if NPT leads to better outcomes for residents. Surely it must do as that is the reason given for the DNAnudge contract (patient and staff safety and well-being together with allocation to wards, surgery etc.). In care homes one of the other benefits should be to allow the normal resumption of visitors to loved ones. Hopefully it is a successful trial as it will provide an important validation but as others have said the products are ready to be sold already and have been for sometime. I think I read they made some tweaks to the Q32 machine recently hence the re-launch.

Here's the 2018 RNS link:

"The q32 complements the smaller, portable q16, which is used in laboratories and in the field and provides customers with an alternative instrument when faced with multiple terrain and off-site testing challenges." So already used in labs.

Graham Mullis, Group CEO of Novacyt, commented:

"The launch of our proprietary genesig® q32 instrument is another important step as we continue to deliver against our growth strategy, which includes product development and is a key focus within our molecular business. Like our genesig® q16 instrument, the q32 is designed to make DNA testing affordable and easy to use. We are pleased by the initial interest shown by our customers with our next-generation q32 and we anticipate strong future sales of this instrument. The q32 launch also builds on the recent launches of the genesig® BKV kit and genesig® EBV kit, as we continue to expand our CE-Mark approved molecular product offering."

https://www.investegate.co.uk/novacyt-s-a---ncyt-/rns/launch-of-next-generation-qpcr-instrument/201905130700047243Y/

It's good news in a way as well - it's a lab in a handheld device well so are our mobile testing machines on site, transportable and capacity to test more than 10-14 tests per day that DNA nudge do. Cheaper per test as well.

Ours are being trialled in care homes at the moment. We have adapted to this near patient model.

Captain suggests all these developments are a threat for Nova not realising it seems that his company is potentially losing out with each new entrant while he waits for his company's test. It seems that the healthcare market and businesses airports will be heading in the direction of rapid testing - anything in the region of 1 hour or so is considered "rapid" - will there therefore be a need for strip tests which may have much lower accuracy?

https://www.independent.co.uk/news/health/coronavirus-uk-news-live-gyms-boris-johnson-second-wave-update-today-a9637371.html

I wonder if this is us?

Cringing

I just checked in quickly yesterday and my response was about the "sentiment" point you raised and that you were investing in companies that had/have poor sentiment but here your advice was to sell because of poor sentiment.

Hopefully you kept your Ocado from those times? That's the hardest part keeping hold of a rising share!

https://www.businessinsider.com/mark-mobius-buy-gold-prices-jump-records-virus-risks-recession-2020-7

A famous fund manager from the old not so favoured now "value" investing style.

@cringsing depends if you're an investor who has considered the fundamentals or a trader. Being contrarian often yields results perhaps not straightaway.

I note that you have ignored sentiment on the shares you have invested in and taken a contrarian approach - consider your Ocado investment when people were "laughing their arses off...". Also your investment in Kier - sentiment has been against it for a while and yet you remain" optimistic" there.

Perhaps you should start following your own advice?

Yes agree shares can be risky and invest what you can afford to lose.

Just a quick look on the Google charts and we were 3.35p on 11th February 2020 and around 3 level fir whole of Feb when GGP was between 4-5 for whole of Feb and 5.68 for that one day when it peaked on 11th Feb. GGP now around 200% higher from those levels in Feb and we are still at Feb levels!

Happy to hold therefore and should be a matter of time before this gets a re-rating. We should now be in the 4-5 range.

https://www.google.com/amp/s/www.telegraph.co.uk/business/2020/07/22/natwest-boss-sees-hybrid-future-working-home-office/amp/

It's happening folks the WFH revolution.

By my rough calculations the value of our stake in ggp and the cash proceeds from the sale of part equal or just exceeds the company's market cap. Everything else is in for free.

I believe the market will re-rate just waiting for the further update/news from the company and it has an exciting portfolio of investments. Imo Dyor.

Good to see you here Scoredagainsteps as well as Imm.

https://www.investegate.co.uk/early-equity-plc--eeqp-/prn/company-investments/20171215165259P4D94/

Another company (Early Equity) that invested in Truspine on 15th December 2017.

Messi1966

Sorry to hear of your troubles. I hope they are resolved to your satisfaction. The public are often subject to fraud and deception and I hope that has not happened in your case. Is it possible you are confused?

Prim are a public company and they would not just hand over a large sum of money without due diligence and that would include meeting the company and directors who are to be the recipients of funds.

Truspine Technologies the holding company is registered at Company's House here is a link:

https://beta.companieshouse.gov.uk/company/09345973/officers

You can see the details of all the directors and Annabel Schild is listed.

There is also the filing history which shows the change from limited company to public. Also the auditor's report by PKF Littlejohn LLP a business used by other Aim companies as well.

If you read the previous posts here you will also find the investor presentations by the company with the details of the directors as well.

If this was a fraud then Prim would have found out about it a long time ago!

I've had my eye on Puretech good long term holding imo.

Arix Bio is another similar one?

It doesn't just have the Lupus drug potential. It has a lot of other tech and potential growth just needs to move some of that forward to bring value for shareholders. Even the
BioAMP-B (Anti-Fungal) and BioGlucagon potential alone if realised would be enough to justify a much a higher valuation. 2022 was suggested for those programs.

A lot of potential let's hope some of it can be realised.

Yes our own biotech specialist for social media! Although as I'm sure Nolupus would say imo dyor and "everyone to their own trades". But it helps to have an experienced view to assist in deliberations.

Just off-topic I'm more in the buy and hold camp but obviously will take profits when appropriate. I don't have good trading skills but am trying to develop those as I think it helps to do a bit a bit of both. I have my core holding here and a trading one as well and I think that's the approach of a lot of fellow investors.

What I'm finding really beneficial (for returns) at the moment is investing small tiny amounts in shares I would normally be hesitant in staking bigger amounts and that approach has been fruitful eg SNG and another share where I invested around the same amount and it's doubled as well. Smaller amounts don't impact the pf in any meaningful way if they don't work out.

I'm not mentioning anything new just some new ways of investing for me LOL. Averaging up not my personal approach but I can see the benefits of it and why NLP does it. I think I would just be scared in getting stuck if there's a retreat that holds for a while before the move up again. I can see that NLP is skilled with this approach and will normally sell the further buys into strength maintaining his core holding?
We can all learn from each other and we are learning all the time and I thought I would put some of my ideas down.

As someone just posted a simple hold.

Just be wary of shorters they have an agenda as well do the rampers at the other extreme.

If a shorter appears ask them for their analysis they usually don't have a sound one or at all.

As I posted last night under the airport thread suddenly it was being touted that the POC test of that company was better than Nova's and it seems that this conclusion was arrived at simply through a BB posters post.

Thanks to the knowledgeable posters here who are able to respond to these weak assertions.

Anyway when I actually looked at the pdf for their test it's not designed for airport testing at all - it's not for asymptomatic cases. Also negative results need testing with molecular and we do not yet know that company's real life sensitivity and specificity yet posters are quick to jump to the alleged and not proven sensitivity of Nova's test in real life scenarios - not a fair or like for like comparison.

Nothing wrong with positive and negative views that's where the balance lies not in shorting or ramping views. Imo Dyor.

Re earlier discussion about the POC BD-Veritor- covid test machine - and whether it is better than PCR. Wbernard already posed the question that if it was better then why are negative results recommended to be retested by molecular?Some more information from a 17 page pdf (if you Google it you can click directly into the pdf - but that doesn't allow me to copy a link here. It's not designed for use on asymptomatic patients and the 84/100% results achieved seem to have been under ideal conditions rather than real world.

LIMITATIONS OF THE PROCEDURE
• Clinical performance was evaluated with frozen samples, and test performance may be different with fresh samples.
• Users should test specimens as quickly as possible after specimen collection.
• Positive test results do not rule out co-infections with other pathogens.
• Results from the BD Veritor System for Rapid Detection of SARS-CoV-2 test should be correlated with the clinical
history, epidemiological data, and other data available to the clinician evaluating thepatient.
• A false-negative test result may occur if the level of viral antigen in a sample is below the detection limit of the test
or if the sample was collected or transported improperly; therefore, a negative test result does not eliminate the
possibility of SARS-CoV-2 infection.
• The amount of antigen in a sample may decrease as the duration of illness increases. Specimens collected after
day 5 of illness are more likely to be negative compared to a RT-PCR assay.
• Failure to follow the test procedure may adversely affect test performance and/or invalidate the testresult.
• The contents of this kit are to be used for the qualitative detection of SARS-CoV-2 antigens from nasal swab

The
BD Veritor System for Rapid Detection of SARS-CoV-2 is designed to detect the presence or absence of SARS-CoV-2
nucleocapsid proteins in respiratory samples from patients with signs and symptoms of infection who are suspected of
COVID-19

SPECIMEN COLLECTION AND HANDLING
Specimen Collection and Preparation
Acceptable specimens for testing with this kit include nasal swab specimens obtained by the dual nares collection method. It
is essential that correct specimen collection and preparation methods be followed. Specimens obtained early during symptom
onset will contain the highest viral titers; specimens obtained after five days of symptoms are more likely to produce negative
results when compared to an RT-PCR assay. Inadequate specimen collection, improper specimen handling
and/or transport may yield a falsely negative result; therefore, training in specimen collection is highly recommended due to
the importance of specimen quality for generating accurate test results.

Negative Test – Negative results are presumptive. Negative test results do not preclude infection and should not be used as
the sole basis for treatment or other patient management decisions, including infection control decisions, particular